Pirfenidone
- Generic Name
- Pirfenidone
- Brand Names
- Esbriet, Pirfenidone axunio (previously Pirfenidone AET), Pirfenidone Viatris
- Drug Type
- Small Molecule
- Chemical Formula
- C12H11NO
- CAS Number
- 53179-13-8
- Unique Ingredient Identifier
- D7NLD2JX7U
- Background
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necro...
- Indication
Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). In Canada and Europe, it is approved in adults only.
- Associated Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Mild Idiopathic Pulmonary Fibrosis, Moderate Idiopathic Pulmonary Fibrosis
- Associated Therapies
- -
Gyre Therapeutics Reports Third Quarter 2024 and Year-To-Date Financial Results and ...
Gyre Therapeutics reported Q3 2024 revenue of $25.5M, down from $32.0M in Q3 2023, and net income of $2.9M, down from $7.5M. The company completed its Phase 3 trial for F351 in CHB-associated liver fibrosis, with data expected in Q1 2025. Planned commercial launches of avatrombopag and nintedanib are set for 2025, and preparations are underway for a U.S. Phase 2 trial of F351 in MASH-associated liver fibrosis. Cash and equivalents stood at $15.9M as of September 30, 2024.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath